Biologics Extremities Spine Bone Growth Products Market Size is Expected to Reach USD 1.81 Billion by 2033, Growing at a CAGR of 3.40%: Straits Research byTim AllenJanuary 23, 2025
Biologics Spine Top Stories Orthofix Announces New President for Bone Growth Therapies Business byJosh SandbergFebruary 29, 2024
Regulatory Top Stories Theragen Receives Two New Patents for Company’s ActaStim® Bone Growth Stimulator System byJosh SandbergDecember 18, 2023
Biologics Spine Top Stories MedTech Breakthrough Recognizes STIM onTrack for Bone Growth Therapy as Best Patient Engagement Mobile App byJosh SandbergMay 4, 2023
Regulatory Spine Top Stories Theragen receives patent for spine fusion bone growth stimulator with digital health data connectivity byJosh SandbergAugust 19, 2022
Biologics Spine Orthofix Expands Synthetic Bone Growth Offerings with Full Market Launch of Opus BA – a Bioactive Solution for Spine Procedures byChris StewartFebruary 22, 2022
Spine Publication of Data Shows High Fusion Rate in Patients Treated with PEMF Therapy Using the Orthofix SpinalStim Device byChris StewartJuly 12, 2021
Extremities Regulatory Orthofix Announces Support for Continued FDA Class III Designation for Bone Growth Stimulators to Ensure Patient Safety and Therapy Efficacy byJosh SandbergFebruary 26, 2020
Top Stories DJO Global, Zimmer-Biomet’s EBI finally escape bone-growth stimulator suit byJosh SandbergApril 14, 2016
